Search Medical Condition
Please enter condition
Please choose location from dropdown

Breast Cancer - HER2 Positive Clinical Trials

A listing of Breast Cancer - HER2 Positive medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (167) clinical trials

DETECT III - A Multicenter Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

The HER2 status in breast cancer patients may change during the course of the disease. In 30% of initially HER2-negative patients with circulating tumor cells (CTC), HER2-positive CTCs can be detected in peripheral blood samples(1). At present, it is unclear if therapy based on the HER2 status of CTC offers ...

Phase

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

Neoadjuvant Chemotherapy (NCT) is a standard treatment of patients who hope breast-conserving therapy (BCT) with locally advanced inoperable breast cancer or large tumor size. it is beneficial to degrading the tumor stage, increasing the rate of surgical resection or the BCT.People who are pathological complete response (pCR) after NCT have ...

Phase

Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into the artery for the treatment of brain metastasis(es) from HER2/neu positive breast cancer. This study will try to determine the best tolerated single dosage of trastuzumab administered into arteries by gradually increasing ...

Phase

BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Neoadjuvant therapy is given to breast cancer patients whose cancers are relatively large or have spread to lymph nodes or both. The primary goal of this treatment is to prevent the cancer from coming back (recurring) elsewhere in the body, but if it makes the cancer in the breast and ...

Phase

A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

150 patients will be prospectively consented/screened. Over the course of the study, 30 patients are expected to develop abnormal strain with a normal EF > 53%. They will be randomized in 1:1 fashion to open label carvedilol vs. no treatment. All consenting patients will receive a baseline echocardiogram and blood ...

Phase

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Patients with HER2-positive tumors >20 mm or verfied regional lymph node metastases are randomized to either arm A, the combination of docetaxel, trastuzumab sc (Herceptin SC) and pertuzumab (Perjeta) or arm B, trastuzumab emtansin (Kadcyla). Switch to the opposite treatment is performed in case of lack of response after evaluations ...

Phase

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of ...

Phase

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic Node Positive HER2 Negative Breast Cancer That is in Remission

PRIMARY OBJECTIVES: I. To assess the safety of 3 escalating doses of a deoxyribonucleic acid (DNA) plasmid based vaccine encoding three breast cancer antigens (insulin-like growth factor-binding protein [IGFBP]-2, HER2, and insulin-like growth factor [IGF]-1 receptor [1R]) in patients with breast cancer. SECONDARY OBJECTIVES: I. To determine the immunogenicity of ...

Phase

Exosomal and Free Extracellular RNAs and Proteins as Predictive. ICORG 10-15 V2

This is a translational pilot study, involving two patient cohorts, designed to identify predictive biomarkers for HER2 targeted therapy, which will be validated in a larger future study. Cohort 1: 300 newly diagnosed (including metastatic) HER2 positive breast cancer patients. Cohort 2: 30 newly diagnosed HER2 negative breast cancer patients. ...

Phase N/A

RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer

A significance,safety and pharmacokinetic of open-label and multicentric Phase Ib/II Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer

Phase